Introduction CA125 in peritoneal dialysis (PD) effluent dialysate has been used as a surrogate biomarker for the health of the peritoneum in PD patients. However CA125 is synthesised by epithelial cells and as such is not specific for the peritoneum, and most studies have only measured peritoneal CA125, without serum CA125 values. As such we wished to determine the factors which influenced PD effluent CA125 in a large contemporaneous cohort. Methods We measured dialysate effluent CA125 in PD patients attending for routine assessment of peritoneal membrane function with a peritoneal equilibration test (PET), with corresponding serum CA125. Results Serum and dialysate CA125 were measured in 205 PD patients; 59.0 ± 16.8 years, median PD treatment 3 (2-20) months, 59 % male, 42.4 % diabetic, with 31.2 % treated by continuous ambulatory peritoneal dialysis, 22 % by automated overnight peritoneal dialysis cycler (APD) and 46.8 % by APD with a day time exchange. The median serum CA125 was 21 (13-38) U/ml, with an effluent 4 h PD PET effluent of 20 (11.5-36.5) U/ml. PET PD effluent dialysate was associated with PET dialysate total protein (b 12.9, p \ 0.001), serum CA125 (b 0.109, p = 0.002), residual renal function (b 0.53, p = 0.018) and age (b 0.145, p = 0.042) and negatively with the number of PD cycles/day (b -2.19, p = 0.001). There was no association with prior peritonitis episodes. Conclusion PD effluent CA125 concentrations were associated with peritoneal protein losses and increased by the usage of higher glucose dialysates to compensate for loss of residual renal function.
Introduction
The peritoneum is lined by a single layer of epithelial cells, which are protected by a mucous barrier formed from a combination of secreted and transmembrane highly glycosylated glycoproteins which create a hydrophilic, lubricating environment protecting the apical cell surface with a mucous coating from foreign particles and invading bacteria. Cancer antigen 125 (CA125), also termed Mucin 16, is the largest of the transmembrane glycoproteins, and binds to mesothelin, a glycophosphatidylinositol glycoprotein, expressed by the peritoneal mesothelium.
In routine clinical practice serum CA125 is used both as a screening test for ovarian cancer, and also to monitor the response to chemotherapy. However as CA125 is produced by the cells lining the peritoneum, effluent dialysate CA125 has been proposed to reflect mesothelial cell mass in stable peritoneal dialysis (PD) patients [1, 2] . However inflammation within the peritoneal cavity will potentially cause an increase in dialysate CA125 concentrations and some reports have reported that effluent CA125 concentrations can increase during an episode of PD peritonitis and then fall with resolution of the infection [3, 4] , although this has not been confirmed in all studies [5] .
More recently peritoneal dialysate effluent CA125 has been used as a biomarker of the general health of peritoneal epithelium, with reports of falling or low CA125 concentrations in patients who develop encapsulating peritoneal sclerosis [6, 7] , and increasing peritoneal effluent CA125 concentrations when patients were switched from standard peritoneal dialysates to more bio-compatible solutions [8] .
These studies have reported on peritoneal dialysate effluent concentrations or production rates, but did not report on peritoneal CA125 in relation to serum concentrations. It has been assumed that peritoneal dialysate effluent CA125 is predominantly produced within the peritoneum, with minimal contribution from that in the blood. However systemic or local peritoneal inflammation could lead to an increase in protein transfer from the vascular compartment to the peritoneal cavity [9] . As such we wished to determine which factors affected the ratio of peritoneal dialysate to serum CA125 in stable PD patients.
Patients and methods
We prospectively measured serum and peritoneal CA125 in a cohort of stable 205 adult patients treated by peritoneal dialysis, when they attended for routine clinical assessment of peritoneal membrane function. No patient had been diagnosed with an episode of PD peritonitis in the preceding 3 months prior to attending for assessment of peritoneal membrane function. A standardised 4-h peritoneal equilibration test (PET) was performed by infusion of 2 l of 2.27 % dialysate solution over 10 min, with the patients in supine position [10] . Patients also brought in samples from their weighed spent dialysate bags so that PD adequacy could be calculated, along with a corresponding 24-h urine collection to determine residual renal function [11] . Peritoneal dialysate creatinine and sodium were corrected for the glucose content of the peritoneal dialysate effluent [11] , and serum albumin by the bromcresol green method, haemoglobin by a standard analyzer [12] , and serum C reactive protein (CRP) by the same method as the UK National Amyloid Centre.
Serum total protein by a modified biuret method (colorimetric assay based on divalent copper reacting in alkaline solution with protein peptide bonds to form a characteristic purple-coloured biuret complex, measuring increased absorbance at 546 nm), and peritoneal dialysate protein using pyrogallol red which complexes with proteins in an acid environment containing molybdate ions, and measuring absorbance at 600 nm [9] . Serum beta-2-microglobulin was measured by rate nephelometry (www. Dako.com, Image 800 analyser, Beckman Coulter, High Wycombe, UK) [13] . Serum and peritoneal dialysate effluent CA125 were measured using a sandwich immunoassay with chemi-luminescence detection (Roche Diagnostics Modular Analytics E170 analyser). Dietary protein intake was estimated using the Randerson equation to obtain a normalised protein nitrogen appearance rate (nPNA) [14] . Patient weight and measurement of intracellular and extracellular water by multifrequency bioimpedance (InBody 720, Seoul, South Korea), using a standardised protocol [15, 16] . Patient co-morbidity was scored using the Stoke-Davies grading scales [17] .
This retrospective audit complied with both the local Royal Free Hospital Research and Development office and the UK NHS guidelines for clinical audit and service development, available at http://www.hra.nhs.uk/docu ments/2013/09/defining-research.pdf, and http://www.gov. uk/government/publications/health-research-ethics-commit tees-governance-arrangements.
Statistical analysis
Data is presented as a mean ± standard deviation, or median and inter-quartile range unless otherwise stated. Standard analysis included Chi square testing with Yates's correction, t test, Man Whitney U test and anova with appropriate Bonferonni or Dunn's testing post analysis. Spearman correlation analysis was performed to identify factors associated with serum and peritoneal CA125. Multiple linear correlation was undertaken in a step backward fashion, including all variables with a p \ 0.1, with nonparametric variables log transformed and then excluding variables which were not significant unless they improved model fit. Statistical analysis was performed with GraphPad (GraphPad version 6.0, Prism, San Diego USA and SPSS, version 22.0, Univ Chicago, Chicago, USA). Statistical significance was taken at p \ 0.05.
Results
The mean age was 59.0 ± 16. The median ratio of dialysate to serum CA125 measured during the PET test was 0.96 (0.53-1.5). There were statistically significant, but weak correlation between both the 4 h dialysate to serum creatinine ratio and peritoneal dialysate effluent CA125 removed [median 183 (111-325) U/min] obtained during the PET, r 2 = 0.07, p \ 0.001, and for the effluent CA125 concentration, r 2 = 0.102, p \ 0.001. Similarly there were weak correlations between serum CA125 concentration and both peritoneal CA125 removed and the CA125 concentration in the peritoneal dialysate effluent (r 2 = 0.08, p \ 0.001, and r 2 = 0.19, p \ 0.001), respectively. As the correlations were marginally stronger we chose the peritoneal dialysate CA125 concentration rather than the removal rate.
PD effluent CA125 has been used as a biomarker of peritoneal mesothelial cell health, we divided patients into those who had a peritoneal dialysate to serum CA125 ratio of \1.0 compared to those with a ratio of C1.0 (Table 1) . Those patients with a low D/S ratio had both lower dialysate effluent CA125 and higher serum concentration ( Fig. 1) . Patients with higher D/S CA125 ratios were larger in size, had greater residual renal function, and lower prescription of higher glucose and 7.5 % icodextrin dialysates. The ratio of dialysate to serum CA125 was associated with 4 h PET dialysate total protein (Fig. 2) , body surface area (r = 0.17, p = 0.014) and residual renal function (r = 0.14, p = 0.43). 45 patients (42.5 %) of those with a low D/P CA125 ratio had suffered a previous episode of peritonitis, which was not different to 31 (31.1 %) for those with a ratio of C1.0. There was no association with estimated dietary protein intake, serum albumin or C reactive protein.
45 patients (22 %) of patients used a neutral pH, bicarbonate containing twin bag glucose containing dialysate. There were no differences in serum CA125 [23 (12- To determine which variables were associated with peritoneal and serum dialysate CA125, simple univariate analysis was performed (supplemental Tables 1 and 2 ). Peritoneal dialysate effluent CA125 was associated with patient age, use of CAPD, residual renal function, faster peritoneal transport status, greater peritoneal protein transport and serum CA125 concentrations. Peritoneal dialysate effluent CA125 was lower in those using more 22.7 % glucose dialysates, APD cycler therapy, and greater peritoneal dialysis small solute clearance. Whereas serum CA125 was associated with peritoneal dialysate CA125, CAPD rather than APD usage, faster peritoneal transport, and negatively with larger body size (supplemental Table 1 ). Multivariable linear analysis was then undertaken in a step backward fashion, eliminating those variables which were not statistically significant, unless they improved model fit. We found that dialysate effluent CA125 was associated with PET protein losses, fewer PD cycles, serum CA125, residual renal function and age (Table 2 ). Whereas serum CA125 was associated with both the ratio of dialysate to serum protein loss (b 559, standard error 117, F value 23.0, t value 4.8, 95 % confidence limits 329-790, p = 0.000), and the number of peritoneal dialysis cycles per day (b -3.5, standard error 1.2, F value 7.7, t value -2.8, 95 % confidence limits -5.9 to -1.0, p = 0.006), with a r 2 model fit of 0.35, and adjusted r 2 value of 0.32. There was no association between dialysate CA125 nor the ratio of dialysate to serum CA125 and previous peritonitis episodes (p = 0.45 and 0.25 respectively). PD CA125 for patients with no previous peritonitis was 21 (13- 
Discussion
Peritoneal dialysate effluent CA125 has been reported to decrease with longer duration of peritoneal dialysis treatment [18] . Peritoneal mesothelial cells constitutively express CA125 on their apical cell membrane [19] , and reduced CA125 expression has been reported to be associated with epithelial to mesenchymal transformation which occurs with increasing exposure to peritoneal dialysates [20] . However in our cross sectional study, the duration of peritoneal dialysis treatment was not associated with peritoneal dialysate CA125 concentrations on univariate analysis, and this may be due to analyzing patients who had been treated for a shorter period.
Previous studies have reported either no differences in peritoneal dialysate effluent CA125 concentrations with icodextrin usage [21] , or greater CA125 with less biocompatible neutral pH, bicarbonate containing dialysates [8] . Our study of more than 200 patients is the largest cross sectional cohort of peritoneal dialysis patients with effluent dialysate CA125 to be reported. We found that there was an effect of peritoneal dialysis prescription and peritoneal dialysate CA125s. Although larger patients would be expected to have a larger peritoneal surface area, we found no association between size and peritoneal dialysate CA125, although there was a univariate association with body fat mass. Patients using the standard four daily exchanges with CAPD had higher PD effluent CA125 concentrations, compared to those using increasing number of overnight cycles with APD based prescriptions, and those with the lower D/P CA125 ratios used less 22.7 g/l dextrose and icodextrin dialysates. Whereas there are reports on CA125 increasing with PD peritonitis [3] , we did not find any association between peritoneal CA125 and previous episodes of peritonitis. Residual renal function was also observed to be associated with increasing PD effluent CA125 concentrations, and as such PD effluent CA125 falls with loss of residual renal function, which is associated with longer peritoneal dialysis treatment, greater requirement for peritoneal small solute clearance and peritoneal ultrafiltration, with greater usage of higher glucose dialysates. Although we did not observe any differences in PD effluent CA125 concentrations in those using standard compared to patients using more biocompatible dialysates; those using the biocompatible dialysates had longer duration of peritoneal dialysis treatment, greater loss of residual renal function and greater user of higher glucose containing dialysates, which may explain the similar results, as a reduction in residual renal function was associated with an increased the use of higher glucose containing dialysates and icodextrin.
We noted that patients with greater PD effluent CA125 concentrations also had greater total peritoneal dialysate protein losses. PD protein loss may reflect local intraperitoneal inflammation, with increased large pore transport [22] . This is supported by the association of PD effluent CA125 and faster peritoneal transport associated with increased peritoneal creatinine transport, in keeping with earlier reports [23] . This relationship between faster transport and increased peritoneal protein transport in patients starting peritoneal dialysis has been reported by others [24] , but may be lost with longer duration of therapy. We also recorded an effect of increasing patient age. Elderly patients are more at risk of sarcopenia, which may be associated with inflammatory conditions [25] and loss of muscle mass [26, 27] . However, this association with peritoneal CA125 may be confounded by more elderly patients in our study being treated with CAPD than APD cyclers.
Whereas many reports have concentrated on PD effluent CA125, we also measured the corresponding serum CA125. Although it may be expected that serum CA125 would increase as residual renal function declines, we found no such association. Similarly whereas it may be expected that larger patients with greater cell mass would have a higher serum CA125, we observed lower serum CA125 concentrations in our larger patients with greater body cell mass. We did however note on univariate analysis that increased peritoneal dialysate small solute clearances, and greater use of peritoneal dialysates were associated with lower serum values, and conversely faster transport status was associated with lower serum CA125 concentrations. This would suggest that peritoneal dialysis may affect serum CA125 concentrations. In addition increasing serum CA125 concentrations would appear to be associated with an inflammatory mileu, as CA125 is also produced by mesothelial cells outside the peritoneal cavity, and this may explain associations with bioimpedance derived measurements of body composition, ECW/TBW ratio, serum sodium, haematocrit and Davies co-morbidity score.
Whereas there a number of reports examining peritoneal clearances of large serum proteins [28, 29] , we were unable to find studies examining whether there was any relationship between dialysate and serum CA125. CA125 is a large molecule of around 220,000 D, and as such would be expected to have slow transport into the peritoneal cavity [28, 29] . We found that serum CA125 concentrations were associated with PD effluent values on both univariate and multivariable analyses, suggesting that PD effluent CA125 may not only depend upon local production and secretion, but could also be possibly affected by serum concentrations. Larger protein transport may be increased in patients recently starting peritoneal dialysis [24] . We observed an association between higher serum CA125 concentrations with fewer peritoneal dialysis exchanges, and greater peritoneal large pore transport. It has been reported that peritoneal losses of some large serum proteins, such as vitamin D binding protein and haptoglobin can lead to significant protein losses with reduced serum concentrations [30] . To explore this further we analysed the ratio of dialysate effluent CA125 to serum CA125. The ratio of dialysate to serum CA125 was higher for larger patients, as larger patients would be expected to have a larger peritoneal surface area with a corresponding greater mesothelial cell mass. However those patients with an increased dialysate to serum CA125 ratio not only had an increased peritoneal CA125 but also a lower serum CA125. Patients with a higher dialysate to serum CA125 ratio had greater residual renal function, which would potentially imply greater renal clearance. Patients with more residual renal function generally have lower extracellular fluid [31] , which would in keeping with the higher serum albumin concentration observed, and suggest that the lower serum CA125 was not simply due to a dilution effect. As the group with the lower dialysate to serum CA125 ratio had less residual renal function they were prescribed higher concentrations of glucose dialysates and icodextrin [32] . Heat sterilisation of glucose dialysates leads to the production of glucose degradation products; including formaldehyde, acetaldehyde, furaldehyde, methylglyoxal, glyoxal and 3-deoxyglucosone [33] , which increase with higher concentrations of glucose so exposing peritoneal mesothelial cells to these potentially toxic substances, with a reduction in peritoneal CA125.
The normal serum reference range for serum CA125 is below 35 U/ml [34] . As such more than 25 % of our healthy peritoneal dialysis cohort had raised serum levels. However it should be recognised that CA125 can also be produced by epithelial tissues elsewhere in the body including ovary, lung, pancreas, breast, stomach, and gall bladder. None of our patients had a diagnosis of epithelial cell cancer, or benign conditions including endometriosis or pelvic inflammatory disease, and equally no patient has been subsequently found to have ovarian or other malignancy. Those patients with the lower dialysate/serum ratio were more likely to have increased serum CA125. However this may have been due to the lower residual renal function in this group, with reduced renal clearance, which is in keeping with previous observations of higher serum CA125 concentrations in both healthy peritoneal dialysis [35] and haemodialysis populations [36] compared to normal control subjects.
Although CA125 in spent peritoneal dialysate is used as a surrogate biomarker for assessing the health of the peritoneum, in our cross sectional study predominantly of patients recently starting peritoneal dialysis, we observed that there was an association between peritoneal and serum CA125 concentrations. We noted that peritoneal CA125 concentrations were greater in those patients with affected faster by increased peritoneal protein transport and greater peritoneal protein losses. Peritoneal CA125 effluent concentrations were also, greater for those using fewer peritoneal dialysis exchange cycles, whether this is simply related to greater removal with more frequent exchanges, or that greater exposure to peritoneal dialysates leads to reduced intra-peritoneal production remains to be elucidated. Peritoneal effluent CA125 dialysate was lower in those with greater and residual renal function, which may reflect greater renal clearance and lower serum concentrations. With loss of residual renal function leading to increased usage of higher glucose concentration dialysates.
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